{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:28:05Z","timestamp":1786490885401,"version":"build-2736575974"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ruth L. Kirschstein National Research Service Award"},{"name":"Institutional Research Training Grant","award":["T32CA229102"],"award-info":[{"award-number":["T32CA229102"]}]},{"name":"University of Alabama Medical Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that contributes disproportionately to thyroid cancer\u2013related mortality. Historically, systemic treatment options for advanced MTC were limited due to poor responsiveness to radioactive iodine and conventional chemotherapy. The development of targeted therapies has significantly transformed disease management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review summarizes current evidence on targeted therapies for advanced MTC, including multikinase inhibitors (MKIs), selective RET inhibitors, and emerging treatment strategies. Literature on efficacy, safety, resistance mechanisms, and novel therapeutic approaches was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>First-generation MKIs, including vandetanib and cabozantinib, demonstrated clinical benefit by targeting RET and angiogenic pathways, though off-target toxicities limited tolerability. More recently, selective RET inhibitors, such as selpercatinib and pralsetinib, have shown high response rates and improved safety profiles, establishing them as preferred first-line therapies for RET-mutant MTC. However, pralsetinib\u2019s recent market withdrawal due to regulatory challenges highlights the need for additional options. Emerging therapies, including BOS172738, SY-5007, and peptide receptor radionuclide therapy, show promising early results. Resistance mechanisms, including gatekeeper and solvent front mutations, remain a challenge. Advances in clinical biomarkers and novel approaches, such as CAR-T cell therapy, may further support personalized treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Targeted therapies have reshaped the management of advanced MTC, with selective RET inhibitors offering improved efficacy and tolerability. Continued research is essential to overcome resistance, expand therapeutic options, and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag300","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:15:57Z","timestamp":1785237357000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeted therapies in the management of advanced medullary thyroid cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9062-6329","authenticated-orcid":false,"given":"Hameeda Arif","family":"Arain","sequence":"first","affiliation":[{"name":"Division of Breast and Endocrine Surgery, Department of Surgery, University of Alabama at Birmingham , Birmingham, AL 35233,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeem","family":"Izhar","sequence":"additional","affiliation":[{"name":"Division of Breast and Endocrine Surgery, Department of Surgery, University of Alabama at Birmingham , Birmingham, AL 35233,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Caretti","sequence":"additional","affiliation":[{"name":"Division of Breast and Endocrine Surgery, Department of Surgery, University of Alabama at Birmingham , Birmingham, AL 35233,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2923-6079","authenticated-orcid":false,"given":"Herbert","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Breast and Endocrine Surgery, Department of Surgery, University of Alabama at Birmingham , Birmingham, AL 35233,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica M","family":"Vodopivec","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham , Birmingham, AL 35233,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2026081118370514300_oyag300-B1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.suronc.2007.08.006","article-title":"Palliation of advanced thyroid malignancies","volume":"16","author":"Greenblatt","year":"2007","journal-title":"Surg Oncol"},{"key":"2026081118370514300_oyag300-B2","doi-asserted-by":"publisher","first-page":"115734","DOI":"10.1016\/j.amjsurg.2024.04.005","article-title":"To infinity and beyond: a historical bibliometric analysis of medullary thyroid carcinoma","volume":"235","author":"Nabata","year":"2024","journal-title":"Am J Surg"},{"key":"2026081118370514300_oyag300-B3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amjsurg.2024.02.009","article-title":"Sex differences and racial\/ethnic disparities in the presentation and treatment of medullary thyroid cancer","volume":"234","author":"Kalva","year":"2024","journal-title":"Am J Surg"},{"key":"2026081118370514300_oyag300-B4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1634\/theoncologist.2013-0053","article-title":"Current understanding and management of medullary thyroid cancer","volume":"18","author":"Roy","year":"2013","journal-title":"Oncologist"},{"key":"2026081118370514300_oyag300-B5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.amjsurg.2022.03.046","article-title":"Ga-DOTATATE-PET shows promise for diagnosis of recurrent or persistent medullary thyroid cancer: a systematic review","volume":"224","author":"Pajak","year":"2022","journal-title":"Am J Surg"},{"key":"2026081118370514300_oyag300-B6","author":"Surveillance Research Program, National Cancer Institute"},{"key":"2026081118370514300_oyag300-B7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000335136","article-title":"Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and notch","volume":"97","author":"Carter","year":"2013","journal-title":"Neuroendocrinology"},{"key":"2026081118370514300_oyag300-B8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3803\/EnM.2021.1082","article-title":"Current guidelines for management of medullary thyroid carcinoma","volume":"36","author":"Kim","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2026081118370514300_oyag300-B9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","article-title":"Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients","volume":"31","author":"Resteghini","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026081118370514300_oyag300-B10","doi-asserted-by":"publisher","first-page":"67661","DOI":"10.18632\/oncotarget.11813","article-title":"Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"2026081118370514300_oyag300-B11","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.xcrm.2023.101332","article-title":"Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers","volume":"4","author":"Nardo","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026081118370514300_oyag300-B12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026081118370514300_oyag300-B13"},{"key":"2026081118370514300_oyag300-B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082104","article-title":"Novel targeted therapies for metastatic thyroid Cancer-A comprehensive review","volume":"12","author":"Al-Jundi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026081118370514300_oyag300-B15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026081118370514300_oyag300-B16","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026081118370514300_oyag300-B17"},{"key":"2026081118370514300_oyag300-B18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3803\/EnM.2020.687","article-title":"Vandetanib for the management of advanced medullary thyroid cancer: a real-world multicenter experience","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2026081118370514300_oyag300-B19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40801-022-00346-y","article-title":"Multikinase inhibitor treatment patterns for advanced thyroid cancer in Japan: an administrative claims database study","volume":"10","author":"Masaki","year":"2023","journal-title":"Drugs Real World Outcomes"},{"key":"2026081118370514300_oyag300-B20","doi-asserted-by":"publisher","first-page":"17588359221101691","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET-altered thyroid cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026081118370514300_oyag300-B21","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with RET-Activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026081118370514300_oyag300-B22","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-Mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"2026081118370514300_oyag300-B23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026081118370514300_oyag300-B24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112639","article-title":"A multicenter randomized phase ii study of single agent efficacy and optimal combination sequence of everolimus and pasireotide lar in advanced thyroid cancer","author":"Bauman","year":"2022"},{"key":"2026081118370514300_oyag300-B25","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","article-title":"A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes","volume":"24","author":"Lim","year":"2013","journal-title":"Ann Oncol"},{"key":"2026081118370514300_oyag300-B26","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","article-title":"Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026081118370514300_oyag300-B27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.852032","article-title":"Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: a sub-analysis based on the ALTER01031 study","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"2026081118370514300_oyag300-B28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026081118370514300_oyag300-B29","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"Lam","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026081118370514300_oyag300-B30","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1210\/jc.2013-3713","article-title":"A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H","volume":"99","author":"Bible","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081118370514300_oyag300-B31","doi-asserted-by":"publisher","first-page":"8598","DOI":"10.1200\/JCO.2025.43.16_suppl.8598","article-title":"Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI na\u00efve or pretreated advanced RET-altered tumors","volume":"43","author":"Alonso","year":"2025","journal-title":"JCO"},{"key":"2026081118370514300_oyag300-B32","doi-asserted-by":"publisher","first-page":"TPS3162","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3162","article-title":"A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer","volume":"37","author":"Schoffski","year":"2019","journal-title":"JCO"},{"key":"2026081118370514300_oyag300-B33","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2021.39.15_suppl.3008","article-title":"BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion\u2009+\u2009NSCLC and RET-mutant MTC: Phase 1 study results","volume":"39","author":"Schoffski","year":"2021","journal-title":"JCO"},{"key":"2026081118370514300_oyag300-B34","author":"Taiho Oncology I","year":"2025"},{"key":"2026081118370514300_oyag300-B35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41392-024-02006-9","article-title":"First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026081118370514300_oyag300-B36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hed.26024","article-title":"Clinical utility of (177) Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity","volume":"42","author":"Parghane","year":"2020","journal-title":"Head Neck"},{"key":"2026081118370514300_oyag300-B37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/MNM.0000000000001205","article-title":"Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-Centre experience","volume":"41","author":"Satapathy","year":"2020","journal-title":"Nucl Med Commun"},{"key":"2026081118370514300_oyag300-B38","author":"Pennsylvania Uo","year":"2025"},{"key":"2026081118370514300_oyag300-B39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40364-023-00522-4","article-title":"Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value","volume":"11","author":"Citarella","year":"2023","journal-title":"Biomark Res"},{"key":"2026081118370514300_oyag300-B40","doi-asserted-by":"publisher","first-page":"e2500067","DOI":"10.1200\/PO-25-00067","article-title":"Circulating tumor DNA as a biomarker for disease surveillance in anaplastic thyroid cancer","volume":"9","author":"Hamidi","year":"2025","journal-title":"JCO Precis Oncol."},{"key":"2026081118370514300_oyag300-B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030724","article-title":"CONUT score: a new tool for predicting prognosis in patients with advanced thyroid cancer treated with TKI","volume":"14","author":"Dalmiglio","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026081118370514300_oyag300-B42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"2026081118370514300_oyag300-B43","doi-asserted-by":"publisher","first-page":"103882","DOI":"10.1016\/j.critrevonc.2022.103882","article-title":"Targeting RET alterations in cancer: recent progress and future directions","volume":"181","author":"Shabbir","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026081118370514300_oyag300-B44","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1002\/hed.26527","article-title":"Neoadjuvant selpercatinib for advanced medullary thyroid cancer","volume":"43","author":"Jozaghi","year":"2021","journal-title":"Head Neck"},{"key":"2026081118370514300_oyag300-B45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2217\/ije.14.26","article-title":"Treating medullary thyroid cancer in the age of targeted therapy","volume":"1","author":"Cabanillas","year":"2014","journal-title":"Int J Endocr Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag300\/70351886\/oyag300.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag300\/70351886\/oyag300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag300\/70351886\/oyag300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:37:15Z","timestamp":1786487835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag300\/8746892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag300","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,29]]},"article-number":"oyag300"}}